Article Text

Download PDFPDF
A rare case of acute hepatitis with jaundice during treatment of human immunodeficiency virus infection with E/C/F/TAF
  1. Hui-Chi Chang1,
  2. Tsung-Chia Chen2,
  3. Hung-Yi Chen3,4
  1. 1 Department of Pharmacy, Taichung Hospital, Ministry of Health and Welfare, Taichung, Taiwan
  2. 2 Division of Infectious Diseases, Department of Internal Medicine, Taichung Hospital, Ministry of Health and Welfare, Taichung, Taiwan
  3. 3 Institute of Pharmacy, China Medical University, Taichung, Taiwan
  4. 4 School of Pharmacy, China Medical University Hospital, Beikang Campus, Taichung, Taiwan
  1. Correspondence to Dr Hung-Yi Chen, The School of Pharmacy, No.91 Hsueh-Shih Road, 40402, R.O.C, Taichung, Taiwan; hungyi{at}


The fixed-dose combination elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide (E/C/F/TAF) is a first-line agent for the treatment of human immunodeficiency virus (HIV) infection. We report the case of a 25-year-old man with newly diagnosed HIV infection who was treated with E/C/F/TAF. The patient's hepatitis panel results were negative. Neither illicit drug abuse nor hepatotoxic medication was reported. Significantly elevated alanine aminotransferase with jaundice was found in the fourth week during the treatment course. His liver function gradually improved after withdrawal of the medication. This is the first report to our knowledge of E/C/F/TAF-related acute hepatitis.

  • gastroenterology
  • hepatobiliary disease
  • infectious diseases
  • HIV & AIDS
  • hepatology
  • toxicology

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.